Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2016-03-14

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acs.jmedchem.5b01499PMID 26878436PMCID PMC5001850
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies

  2016cited by this paper
• Nociceptin/orphanin FQ peptide receptor antagonist JTC‐801 reverses pain and anxiety symptoms in a rat model of post‐traumatic stress disorder

  2015cited by this paper
• Mechanical hyperalgesia in rats with diabetic polyneuropathy is selectively inhibited by local peripheral nociceptin/orphanin FQ receptor and µ-opioid receptor agonism.

  2015cited by this paper
• Small-molecule nociceptin receptor agonist ameliorates mast cell activation and pain in sickle mice

  2015cited by this paper
• Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist.

  2015cited by this paper
• Cebranopadol: a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors

  2015cited by this paper
• Acute and subchronic antinociceptive effects of nociceptin/orphanin FQ receptor agonists infused by intrathecal route in rats.

  2015cited by this paper
• MT‐7716, a potent NOP receptor agonist, preferentially reduces ethanol seeking and reinforcement in post‐dependent rats

  2015cited by this paper
• Supraspinal actions of nociceptin/orphanin FQ, morphine and substance P in regulating pain and itch in non‐human primates

  2015cited by this paper
• Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats.

  2014cited by this paper
• Functional plasticity of the N/OFQ‐NOP receptor system determines analgesic properties of NOP receptor agonists

  2014cited by this paper
• Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain

  2014cited by this paper
• Retest imaging of [11C]NOP-1A binding to nociceptin/orphanin FQ peptide (NOP) receptors in the brain of healthy humans

  2014cited by this paper
• Design, synthesis and evaluation of [(3)H]PF-7191, a highly specific nociceptin opioid peptide (NOP) receptor radiotracer for in vivo receptor occupancy (RO) studies.

  2014cited by this paper
• Cebranopadol: A Novel Potent Analgesic Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist

  2014cited by this paper
• The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.

  2014cited by this paper
• Activation of the endogenous nociceptin system by selective nociceptin receptor agonist SCH 221510 produces antitransit and antinociceptive effect: a novel strategy for treatment of diarrhea‐predominant IBS

  2014cited by this paper
• Anti-Inflammatory and Antinociceptive Action of an Orally Available Nociceptin Receptor Agonist SCH 221510 in a Mouse Model of Inflammatory Bowel Diseases

  2014cited by this paper
• The endogenous nociceptin/orphanin FQ‐NOP receptor system as a potential therapeutic target for intestinal disorders

  2014cited by this paper
• Chronic Treatment with Novel Brain-Penetrating Selective NOP Receptor Agonist MT-7716 Reduces Alcohol Drinking and Seeking in the Rat

  2014cited by this paper
• Operant nociception in nonhuman primates

  2014cited by this paper
• Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK‐21273 in comparison with SB‐612111

  2013cited by this paper
• A Review of the NOP (ORL-1)-Nociceptin/Orphanin FQ System Covering Receptor Structure, Distribution, Role in Analgesia and Reward and Interactions with Other Receptors

  2013cited by this paper
• Pharmacological Investigation of NOP-Related Ligands as Analgesics without Abuse Liability

  2013cited by this paper
• The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.

  2013cited by this paper
• Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs.

  2013cited by this paper
• Evaluation of [18F]MK-0911, a positron emission tomography (PET) tracer for opioid receptor-like 1 (ORL1), in rhesus monkey and human

  2013cited by this paper
• Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair

  2012cited by this paper
• Brain and Whole-Body Imaging of Nociceptin/Orphanin FQ Peptide Receptor in Humans Using the PET Ligand 11C-NOP-1A

  2012cited by this paper
• Roles of Mu Opioid Receptors and Nociceptin/Orphanin FQ Peptide Receptors in Buprenorphine-Induced Physiological Responses in Primates

  2012cited by this paper
• Structure of the Nociceptin/Orphanin FQ Receptor in Complex with a Peptide Mimetic

  2012cited by this paper
• Development of LC-MS/MS-based receptor occupancy tracers and positron emission tomography radioligands for the nociceptin/orphanin FQ (NOP) receptor.

  2012cited by this paper
• The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.

  2011cited by this paper
• The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide (SCH 655842): comparison of efficacy and side effects across rodent species.

  2011cited by this paper
• Activation of brain NOP receptors attenuates acute and protracted alcohol withdrawal symptoms in the rat.

  2011cited by this paper
• Synthesis and evaluation of radioligands for imaging brain nociceptin/orphanin FQ peptide (NOP) receptors with positron emission tomography.

  2011cited by this paper
• Brain and Whole-Body Imaging in Rhesus Monkeys of 11C-NOP-1A, a Promising PET Radioligand for Nociceptin/Orphanin FQ Peptide Receptors

  2011cited by this paper
• Where Are the New Cough Treatments: A Debriefing of Recent Clinical Proof-of-Concept Trials with the NOP Agonist SCH 486757

  2011cited by this paper
• Differential Effects of Nociceptin/Orphanin FQ (NOP) Receptor Agonists in Acute versus Chronic Pain: Studies with Bifunctional NOP/μ Receptor Agonists in the Sciatic Nerve Ligation Chronic Pain Model in Mice

  2011cited by this paper
• Bioanalytics and pharmacokinetics of the nociceptin/orphanin FQ peptide receptor agonist RO0646198 in Wistar rats and Cynomolgus monkeys.

  2010cited by this paper
• Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4).

  2010cited by this paper
• Long‐lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP‐112

  2010cited by this paper
• Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relat

  2010cited by this paper
• Effects of the NOP receptor agonist Ro65-6570 on the acquisition of opiate- and psychostimulant-induced conditioned place preference in rats.

  2010cited by this paper
• The nociceptin/orphanin FQ system as a target for treating alcoholism.

  2010cited by this paper
• Role of innate and drug-induced dysregulation of brain stress and arousal systems in addiction: Focus on corticotropin-releasing factor, nociceptin/orphanin FQ, and orexin/hypocretin.

  2010cited by this paper
• Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models.

  2010cited by this paper
• Brain Interstitial Nociceptin/Orphanin FQ Levels are Elevated in Parkinson's Disease

  2010cited by this paper
• Recently patented and promising ORL-1 ligands: where have we been and where are we going?

  2010cited by this paper
• The effects of nociceptin/orphanin FQ receptor agonist Ro 64-6198 and diazepam on antinociception and remifentanil self-administration in rhesus monkeys

  2010cited by this paper
• Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24.

  2009cited by this paper
• Identification of an orally active opioid receptor-like 1 (ORL1) receptor antagonist 4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine as clinical candidate.

  2009cited by this paper
• Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120.

  2009cited by this paper
• Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys.

  2009cited by this paper
• Chronic treatment with the selective NOP receptor antagonist [Nphe1,Arg14,Lys15]N/OFQ-NH2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats

  2009cited by this paper
• Comparison of the Antinociceptive and Antirewarding Profiles of Novel Bifunctional Nociceptin Receptor/μ-Opioid Receptor Ligands: Implications for Therapeutic Applications

  2009cited by this paper
• The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety.

  2009cited by this paper
• Nociceptin/Orphanin FQ Peptide Receptor Agonist Ac-RYYRWKKKKKKK-NH2 (ZP120) Induces Antinatriuresis in Rats by Stimulation of Amiloride-Sensitive Sodium Reabsorption

  2009cited by this paper
• Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent antianxiety drug.

  2009cited by this paper
• Effect of a Novel NOP Receptor Agonist (SCH 225288) on Guinea Pig Irritant-Evoked, Feline Mechanically Induced and Canine Infectious Tracheobronchitis Cough

  2009cited by this paper
• Behavioral Effects of a Synthetic Agonist Selective for Nociceptin/Orphanin FQ Peptide Receptors in Monkeys

  2009cited by this paper
• The Efficacy of a NOP1 Agonist (SCH486757) in Subacute Cough

  2009cited by this paper
• The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential

  2008cited by this paper
• Effects of nociceptin/orphanin FQ receptor (NOP) agonist, Ro64-6198, on reactivity to acute pain in mice: comparison to morphine.

  2008cited by this paper
• Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism.

  2008cited by this paper
• The Anxiolytic-Like Effects of the Novel, Orally Active Nociceptin Opioid Receptor Agonist 8-[bis(2-Methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510)

  2008cited by this paper
• Functional antagonism between nociceptin/orphanin FQ (N/OFQ) and corticotropin-releasing factor (CRF) in the rat brain: evidence for involvement of the bed nucleus of the stria terminalis

  2008cited by this paper
• Nociceptin/orphanin FQ peptide receptor as a therapeutic target for obesity.

  2008cited by this paper
• The novel nociceptin/orphanin FQ receptor antagonist Trap‐101 alleviates experimental parkinsonism through inhibition of the nigro‐thalamic pathway: positive interaction with L‐DOPA

  2008cited by this paper
• Pharmacological characterization of the newly synthesized nociceptin/orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole as an anxiolytic agent.

  2008cited by this paper
• Activation of the nociceptin opioid system in rat sensory neurons produces antinociceptive effects in inflammatory pain: Involvement of inflammatory mediators

  2007cited by this paper
• Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In Vivo Studies

  2007cited by this paper
• The Nociceptin/Orphanin FQ Receptor Agonist Ro 64-6198 Reduces Alcohol Self-Administration and Prevents Relapse-Like Alcohol Drinking

  2007cited by this paper
• Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In Vitro Studies

  2007cited by this paper
• The Hypnotic, Electroencephalographic, and Antinociceptive Properties of Nonpeptide ORL1 Receptor Agonists After Intravenous Injection in Rodents

  2007cited by this paper
• Effect of nociceptin in acid-evoked cough and airway sensory nerve activation in guinea pigs.

  2006cited by this paper
• Daily intravesical instillation of 1 mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study.

  2006cited by this paper
• Effects of Intrathecally Administered Nociceptin/Orphanin FQ in Monkeys: Behavioral and Mass Spectrometric Studies

  2006cited by this paper
• UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor.

  2006cited by this paper
• Nociceptin and its receptor in rat dorsal root ganglion neurons in neuropathic and inflammatory pain models: implications on pain processing

  2006cited by this paper
• Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity.

  2006cited by this paper
• Effect of novel nociceptin/orphanin FQ-NOP receptor ligands on ethanol drinking in alcohol-preferring msP rats.

  2006cited by this paper
• Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands

  2006cited by this paper
• Spinal and local peripheral antiallodynic activity of Ro64‐6198 in neuropathic pain in the rat

  2005cited by this paper
• The effect of a systemically active ORL-1 agonist, Ro 64-6198, on the acquisition, expression, extinction, and reinstatement of morphine conditioned place preference.

  2005cited by this paper
• Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): Ligand-based analysis of structural factors influencing intrinsic activity at NOP

  2005cited by this paper
• Pharmacodynamic Characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a Novel, Functionally Selective Nociceptin/Orphanin FQ Peptide Receptor Partial Agonist with Sodium-Potassium-Sparing Aquaretic Activity

  2005cited by this paper
• Blockade of Nociceptin/Orphanin FQ Transmission Attenuates Symptoms and Neurodegeneration Associated with Parkinson's Disease

  2005cited by this paper
• Nonphotic entrainment of the circadian body temperature rhythm by the selective ORL1 receptor agonist W‐212393 in rats

  2005cited by this paper
• Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species

  2005cited by this paper
• Recent advances towards the discovery of ORL-1 receptor agonists and antagonists

  2005cited by this paper
• The neural circuitry of reward and its relevance to psychiatric disorders

  2004cited by this paper
• Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice

  2004cited by this paper
• Modification of Nociception and Morphine Tolerance by the Selective Opiate Receptor-Like Orphan Receptor Antagonist (–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111)

  2004cited by this paper
• Blockade of Nociceptin/Orphanin FQ Receptor Signaling in Rat Substantia Nigra Pars Reticulata Stimulates Nigrostriatal Dopaminergic Transmission and Motor Behavior

  2004cited by this paper
• Antitussive Profile of the NOP Agonist Ro-64-6198 in the Guinea Pig

  2004cited by this paper
• A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor.

  2004cited by this paper
• The Opioid Receptor Like-1 Receptor Agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one) Produces a Discriminative Stimulus in Rats Distinct from That of a μ, κ, and δ Opioid Receptor Agonist Cue

  2004cited by this paper
• The NOP (ORL1) receptor antagonist Compound B stimulates mesolimbic dopamine release and is rewarding in mice by a non‐NOP‐receptor‐mediated mechanism

  2004cited by this paper
• Autoradiographic localization of (125)i[Tyr(14)] nociceptin/orphanin FQ binding sites in macaque primate CNS.

  2003cited by this paper

• Opioid Antagonists as a Potential Novel Class of Psychopharmacological Agents for Management of Anhedonia

  2026cites this paper
• The Role of Clinical Pharmacogenetics and Opioid Interactions in Pain Management: Current Evidence and Future Perspectives

  2026cites this paper
• The Therapeutic Potential of Dual NMR (NOP/MOP) Agonism in Pain Management

  2025cites this paper
• Therapeutic exploration of biased ligands at class A G protein-coupled receptors over the past 20 years.

  2025cites this paper
• Nociceptin/OrphaninFQ Receptor Modulates the Maturation of Adult-Born Neurons in the Mouse Dentate Gyrus Under Physiological Conditions and in a Chronic Stress Model

  2025cites this paper
• Efficacy and safety of a selective partial agonist for nociception/orphanin‐FQ peptide (NOP) receptors in patients with insomnia disorder

  2025cites this paper
• Effects of the μ-opioid peptide and nociceptin/orphanin FQ peptide receptor agonist BU08028 on cocaine self-administration in male rhesus monkeys.

  2025cites this paper
• Opioid modulation of prefrontal cortex cells and circuits.

  2024cites this paper
• Small molecule NOP agonists reverse locomotor sensitization induced by cocaine in male C57BL/6 mice.

  2024cites this paper
• Expression heterogeneity, tumor immune characteristics and the prognosis effects of OPRL1 in patients with tumors: a pan-cancer study combined with bioinformation analyses and in vitro validation

  2024cites this paper
• Nuclear Factor-κB Signaling Regulates the Nociceptin Receptor but Not Nociceptin Itself

  2024cites this paper
• The μ-opioid receptor differentiates two distinct human nociceptive populations relevant to clinical pain

  2024cites this paper
• A Multi-Angle Approach to Predict Peptide-GPCR Complexes: The N/OFQ-NOP System as a Successful AlphaFold Application Case Study

  2024cites this paper
• Treatment of insomnia associated with alcohol and opioid use: a narrative review

  2024cites this paper
• Investigating the neurobiology of maternal opioid use disorder and prenatal opioid exposure using brain organoid technology

  2024cites this paper
• Exploring the binding interactions of NOP receptor with designed natural phytochemical-neuropeptide conjugates: an in silico and SPR study

  2024cites this paper
• The Downregulation of Opioid Receptors and Neuropathic Pain

  2023cites this paper
• Computational Design of Plant‐Based Antistress Agents Targeting Nociceptin Receptor

  2023cites this paper
• Targeting Nociceptin/Orphanin FQ receptor to rescue cognitive symptoms in a mouse neuroendocrine model of chronic stress

  2023cites this paper
• μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges

  2023cites this paper
• Acute single non-sedative doses of NOP receptor agonists affect acquisition of object location memory but repeated high doses do not induce long-lasting deficits.

  2023cites this paper
• Discovery and structure-activity relationships (SAR) of a novel class of 2-substituted N-piperidinyl indole-based nociceptin opioid receptor ligands.

  2023cites this paper
• Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics

  2023cites this paper
• Endometriosis and Opioid Receptors: Are Opioids a Possible/Promising Treatment for Endometriosis?

  2023cites this paper
• Advances and prospects

  2022cites this paper
• Receptors

  2022cites this paper
• Key differences in regulation of opioid receptors localized to presynaptic terminals compared to somas: Relevance for novel therapeutics.

  2022cites this paper
• Regulation of N-type calcium channels by nociceptin receptors and its possible role in neurological disorders

  2022cites this paper
• A Crosstalk between the Cannabinoid Receptors and Nociceptin Receptors in Colitis—Clinical Implications

  2022cites this paper
• Synthesis, Biological Activity and Molecular Docking of Chimeric Peptides Targeting Opioid and NOP Receptors

  2022cites this paper
• Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?

  2022cites this paper
• Spotlight on Nociceptin/Orphanin FQ Receptor in the Treatment of Pain

  2022cites this paper
• Sex differences in the effect of chronic delivery of the buprenorphine analogue BU08028 on heroin relapse and choice in a rat model of opioid maintenance

  2021cites this paper
• Label-free cell phenotypic study of opioid receptors and discovery of novel mu opioid ligands from natural products.

  2021cites this paper
• A new synthetic protectin D1 analog 3-oxa-PD1n-3 DPA reduces neuropathic pain and chronic itch in mice.

  2021cites this paper
• Novel Treatments for Chronic Pain: Moving Beyond Opioids.

  2021cites this paper
• Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists

  2021cites this paper
• Kratom Alkaloids as Probes for Opioid Receptor Function: Pharmacological Characterization of Minor Indole and Oxindole Alkaloids from Kratom.

  2021cites this paper
• Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors.

  2021cites this paper
• Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology.

  2021cites this paper
• Molecular mechanisms of opioid tolerance: From opioid receptors to inflammatory mediators (Review)

  2021cites this paper
• NOP receptor antagonism attenuates reinstatement of alcohol-seeking through modulation of the mesolimbic circuitry in male and female alcohol-preferring rats

  2021cites this paper
• The Role of Nociceptin in Opioid Regulation of Brain Functions

  2021cites this paper
• Therapeutic potential of nociceptin/orphanin FQ peptide (NOP) receptor modulators for treatment of traumatic brain injury, traumatic stress, and their co-morbidities.

  2021cites this paper
• NOP01, a NOP receptor agonist, produced potent and peripherally restricted antinociception in a formalin-induced mouse orofacial pain model.

  2021cites this paper
• Role of Nociceptin/Orphanin FQ-NOP Receptor System in the Regulation of Stress-Related Disorders

  2021cites this paper
• Research progress on the potential novel analgesic BU08028.

  2021cites this paper
• Lack of effect of the nociceptin opioid peptide agonist Ro 64-6198 on pain-depressed behavior and heroin choice in rats.

  2021cites this paper
• Potential of Nociceptin/Orphanin FQ Peptide Analogs for Drug Development

  2020cites this paper
• Buprenorphine Exposure Alters the Development and Migration of Interneurons in the Cortex

  2020cites this paper
• Nociceptin/orphanin FQ peptide receptor-related ligands as novel analgesics.

  2020cites this paper
• Post-translational Modifications of Opioid Receptors.

  2020cites this paper
• Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse

  2020influential citation
• Managing Parkinson's disease: moving ON with NOP

  2020influential citation
• Targeted Identification of Protein Interactions in Eukaryotic mRNA Translation

  2020cites this paper
• AT-121, ¿el opioide perfecto?

  2020cites this paper
• Exacerbated Headache-Related Pain in the Single Prolonged Stress Preclinical Model of Post-traumatic Stress Disorder

  2020cites this paper
• Discovery and Structure-activity Relationships of Nociceptin Receptor Partial Agonists that Afford Symptom Ablation in Parkinson's Disease Models.

  2020cites this paper
• Targeting opioid dysregulation in depression for the development of novel therapeutics.

  2019influential citation
• NOP-Targeted Nonpeptide Ligands.

  2019cites this paper
• Opioid-induced endocrinopathies.

  2019cites this paper
• Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys

  2019cites this paper
• Neurologic, Cognitive, and Behavioral Consequences of Opioid Overdose: a Review

  2019cites this paper
• Effects of NOP-Related Ligands in Nonhuman Primates.

  2019cites this paper
• Pain And Opioid Systems, Implications In The Opioid Epidemic.

  2019cites this paper
• Nociceptin/orphanin FQ receptor modulates painful and fatigue symptoms in a mouse model of fibromyalgia.

  2019cites this paper
• Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094).

  2019cites this paper
• BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates.

  2019cites this paper
• NOP-Targeted Peptide Ligands.

  2019cites this paper
• ERK and p38 contribute to the regulation of nociceptin and the nociceptin receptor in human peripheral blood leukocytes

  2019cites this paper
• A Survey of Molecular Imaging of Opioid Receptors

  2019cites this paper
• Biochemical and pharmacological investigation of novel nociceptin/OFQ analogues and N/OFQ‐RYYRIK hybrid peptides

  2019cites this paper
• Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists

  2019cites this paper
• University of Birmingham Opioid-induced endocrinopathies

  2019cites this paper
• NIDA’s medication development priorities in response to the Opioid Crisis: ten most wanted

  2018cites this paper
• Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists

  2018cites this paper
• Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic

  2018cites this paper
• NOP receptor pharmacological profile – A dynamic mass redistribution study

  2018cites this paper
• Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.

  2018cites this paper
• Opioid receptors: drivers to addiction?

  2018cites this paper
• A Novel and Selective Nociceptin Receptor (NOP) Agonist (1‐(1‐((cis)‐4‐isopropylcyclohexyl)piperidin‐4‐yl)‐1H‐indol‐2‐yl)methanol (AT‐312) Decreases Acquisition of Ethanol‐Induced Conditioned Place Preference in Mice

  2018influential citation
• Peptide welding technology – A simple strategy for generating innovative ligands for G protein coupled receptors

  2018cites this paper
• Anti‐Parkinsonian and anti‐dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists

  2018influential citation
• Nociceptin/orphanin FQ receptors modulate the discriminative stimulus effects of oxycodone in C57BL/6 mice.

  2018cites this paper
• The Literature of Heterocyclic Chemistry, Part XVI, 2016

  2018cites this paper
• Are Opioids Effective in Relieving Neuropathic Pain?

  2018cites this paper
• Attenuating the Agent: Reducing Opioid “Virulence”

  2018cites this paper
• The Nociceptin Receptor (NOP) Agonist AT-312 Blocks Acquisition of Morphine- and Cocaine-Induced Conditioned Place Preference in Mice

  2018cites this paper
• Curcumin downregulates expression of opioid-related nociceptin receptor gene (OPRL1) in isolated neuroglia cells.

  2018cites this paper
• The Nociceptin/Orphanin FQ System and the Regulation of Memory.

  2018cites this paper
• UC Office of the President Recent Work Title The Nociceptin Receptor ( NOP ) Agonist AT-312 Blocks Acquisition of Morphine-and Cocaine-Induced Conditioned Place Preference in Mice Permalink

  2018cites this paper
• A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates

  2018cites this paper
• Activation of nociceptin/orphanin FQ receptors inhibits contextual fear memory reconsolidation.

  2017cites this paper
• Cebranopadol: novel dual opioid/NOP receptor agonist analgesic

  2017cites this paper
• In vitro pharmacological characterization of a novel unbiased NOP receptor‐selective nonpeptide agonist AT‐403

  2017cites this paper
• In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.

  2016cites this paper
• Treatment of Pain with Spirocylic Cyclohexane Derivatives Having Dual Specificity for ORL-1 and μ-Opioid Receptors.

  2016cites this paper
• Modified Synthesis of NOP Receptor Antagonist SB612111

  2016cites this paper
• A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates

  2016cites this paper
• Nociceptin and the NOP Receptor in Pain Management: From Molecular Insights to Clinical Applications

  year unknowninfluential citation